Abstract

Research Article

The Role of Buspirone in the Treatment of Patients with Paranoid Schizophrenia with Non-Suicidal Auto Aggression Who Have Had a Coronavirus Infection

IV Kravchenko*

Published: 21 June, 2023 | Volume 7 - Issue 1 | Pages: 010-014

The relevance of this work is due to the insufficient number of modern studies on the treatment of patients with paranoid schizophrenia with non-suicidal autoaggressive actions or in short: “NSAA”, who have had a coronavirus infection. The aim of the study was to study the role of buspirone in the complex therapy of patients with paranoid schizophrenia with NSAA who had a coronavirus infection. 
Materials and research methods: 99 patients with paranoid schizophrenia meeting ICD-10 criteria were examined by a continuous, non-randomized clinical method. Fisher’s test was used for statistical evaluation. 
Results: It was established that the consequence of the coronavirus infection was an increase in the proportion of residual organic changes in the form of manifestations of the dysphoric syndrome, specific changes in the cognitive sphere, and the autonomic nervous system. The manifestations of dysphoria included an increase in the frequency of openly manifested aggression, anxiety, impulsivity, and the implementation of NSAA by the type of affective discharge. The structure of acquired cognitive impairments consisted of changes in thinking by the type of thoroughness, and rigidity of perseveration. Changes in the autonomic nervous system are presented in the form of diencephalic crises. Also, psychotic states not characteristic of the previously examined patients were noted, such as twilight stupefaction, delusional symptoms of Cappgras, Fregoli, and tactile hallucinosis. It has been established that the use of buspirone as part of complex therapy with neuroleptics, compared with monotherapy with neuroleptics, increases the effectiveness of therapy in relation to these clinical manifestations in the studied individuals. 
Conclusion: The use of buspirone in combination with neuroleptic drugs increases the effectiveness of therapy in relation to the leading psychopathological manifestations in patients with paranoid schizophrenia with NSAA who have undergone coronavirus infection.

Read Full Article HTML DOI: 10.29328/journal.apmh.1001047 Cite this Article Read Full Article PDF

Keywords:

Paranoid schizophrenia; Non-suicidal autoaggression; Coronavirus infection; Buspirone

References

  1. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA Neurol. 2020 Aug 1;77(8):1018-1027. doi: 10.1001/jamaneurol.2020.2065. PMID: 32469387; PMCID: PMC7484225.
  2. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, Sejvar J, Solomon T. Neurological associations of COVID-19. Lancet Neurol. 2020 Sep;19(9):767-783. doi: 10.1016/S1474-4422(20)30221-0. Epub 2020 Jul 2. PMID: 32622375; PMCID: PMC7332267.
  3. Zhou L, Zhang M, Wang J, Gao J. Sars-CoV-2: Underestimated damage to nervous system. Travel Med Infect Dis. 2020 Jul-Aug;36:101642. doi: 10.1016/j.tmaid.2020.101642. Epub 2020 Mar 24. PMID: 32220634; PMCID: PMC7269702.
  4. Najjar S, Najjar A, Chong DJ, Pramanik BK, Kirsch C, Kuzniecky RI, Pacia SV, Azhar S. Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. J Neuroinflammation. 2020 Aug 6;17(1):231. doi: 10.1186/s12974-020-01896-0. PMID: 32758257; PMCID: PMC7406702.
  5. Kumari P, Rothan HA, Natekar JP, Stone S, Pathak H, Strate PG, Arora K, Brinton MA, Kumar M. Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice. Viruses. 2021 Jan 19;13(1):132. doi: 10.3390/v13010132. PMID: 33477869; PMCID: PMC7832889.
  6. Khasanova DR, Jitkova YuV, Vaskaeva GR. Post-COVID syndrome: review of knowledge of pathogenesis, neuropsyhiatriс manifestations and treatment perspectives. Nevrologia, Neuropsychiatriya, Psychosomatika. 2021; 13(3):93-98 (in Russ.)]. DOI: 10.14412/2074-2711-2021-3-93-98].
  7. Hromić-Jahjefendić A, Barh D, Uversky V, Aljabali AA, Tambuwala MM, Alzahrani KJ, Alzahrani FM, Alshammeri S, Lundstrom K. Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to? Vaccines (Basel). 2023 Jan 17;11(2):208. doi: 10.3390/vaccines11020208. PMID: 36851087; PMCID: PMC9960675.
  8. Sumiyoshi T, Higuchi Y. Facilitative effect of serotonin(1A) receptor agonists on cognition in patients with schizophrenia. Curr Med Chem. 2013;20(3):357-62. PMID: 23157627.
  9. Palomar-Ciria N, Blanco Del Valle P, Hernández-Las Heras MÁ, Martínez-Gallardo R. Schizophrenia and COVID-19 delirium. Psychiatry Res. 2020 Aug;290:113137. doi: 10.1016/j.psychres.2020.113137. Epub 2020 May 27. PMID: 32485483; PMCID: PMC7251413.
  10. Maguire PA, Looi JC. Vulnerability of people with schizophrenia to COVID-19. Aust N Z J Psychiatry. 2020 Oct;54(10):1044. doi: 10.1177/0004867420940775. Epub 2020 Jul 2. PMID: 32615791.
  11. Ma J, Jiang T, Huang H, Li R, Zhang L, Liu L, Liu X. Mental Symptoms and Stress of Hospitalized Schizophrenia Patients With 2019 Novel Coronavirus Disease: An Observation Study. Front Psychiatry. 2021 Apr 9;12:557611. doi: 10.3389/fpsyt.2021.557611. PMID: 33897476; PMCID: PMC8062770.
  12. Barlati S, Nibbio G, Vita A. Schizophrenia during the COVID-19 pandemic. Curr Opin Psychiatry. 2021 May 1;34(3):203-210. doi: 10.1097/YCO.0000000000000702. PMID: 33587494; PMCID: PMC9583890.
  13. Tzur Bitan D, Krieger I, Kridin K, Komantscher D, Scheinman Y, Weinstein O, Cohen AD, Cicurel AA, Feingold D. COVID-19 Prevalence and Mortality Among Schizophrenia Patients: A Large-Scale Retrospective Cohort Study. Schizophr Bull. 2021 Aug 21;47(5):1211-1217. doi: 10.1093/schbul/sbab012. PMID: 33604657; PMCID: PMC7928567.
  14. Caqueo-Urízar A, Urzúa A, Ponce-Correa F, Ferrer R. Psychosocial Effects of the COVID-19 Pandemic on Patients With Schizophrenia and Their Caregivers. Front Psychol. 2021 Nov 5;12:729793. doi: 10.3389/fpsyg.2021.729793. PMID: 34803806; PMCID: PMC8602112.
  15. Pourfridoni M, Askarpour H. COVID-19 and the increase in schizophrenia incidence in the future: A hypothesis and a serious warning. Health Sci Rep. 2022 Dec 5;6(1):e978. doi: 10.1002/hsr2.978. PMID: 36479392; PMCID: PMC9721364.
  16. Pardamean E, Roan W, Iskandar KTA, Prayangga R, Hariyanto TI. Mortality from coronavirus disease 2019 (Covid-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry. 2022 Mar-Apr;75:61-67. doi: 10.1016/j.genhosppsych.2022.01.010. Epub 2022 Feb 4. PMID: 35182908; PMCID: PMC8813760.
  17. Haddad C, Chamoun A, Sacre H, Hallit S, Salameh P, Calvet B. Cognitive function in recovered COVID-19 Lebanese patients with schizophrenia. Ann Gen Psychiatry. 2023 Mar 11;22(1):7. doi: 10.1186/s12991-023-00435-4. PMID: 36906570; PMCID: PMC10008071.
  18. Seyedmirzaei H, Katebian S, Pourkand D, Cattarinussi G, Sambataro F, Brambilla P, Delvecchio G. Effects of COVID-19 pandemic on depression in patients with schizophrenia: A mini-review of the current evidence. J Affect Disord. 2023 Jul 1;332:143-149. doi: 10.1016/j.jad.2023.03.087. Epub 2023 Mar 31. PMID: 37003432; PMCID: PMC10063456.
  19. Kishi T, Meltzer HY, Iwata N. Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis. Int J Neuropsychopharmacol. 2013 Jul;16(6):1259-66. doi: 10.1017/S1461145713000151. Epub 2013 Apr 3. PMID: 23551924.
  20. Sheikhmoonesi F, Zarghami M, Bahari Saravi SF, Khalilian A, Ala S. A triple-blinded, randomized, placebo-controlled trial to examine the efficacy of buspirone added to typical antipsychotic drugs in patients with chronic schizophrenia. J Res Med Sci. 2015 Feb;20(2):140-5. PMID: 25983765; PMCID: PMC4400707.
  21. Yamada R, Wada A, Stickley A, Yokoi Y, Sumiyoshi T. Effect of 5-HT1A Receptor Partial Agonists of the Azapirone Class as an Add-On Therapy on Psychopathology and Cognition in Schizophrenia: A Systematic Review and Meta-Analysis. Int J Neuropsychopharmacol. 2023 Apr 17;26(4):249-258. doi: 10.1093/ijnp/pyad004. PMID: 36721972; PMCID: PMC10109009.

Figures:

Similar Articles

Recently Viewed

  • Membranous nephropathy complicating relapsing polychondritis: A case report
    Christopher Rice, Vatsalya Kosuru, John Jason White, Christine Van Beek, Rachel Elam*, Michael Clemenshaw, Laura Carbone and Leighton James Christopher Rice,Vatsalya Kosuru,John Jason White,Christine Van Beek,Rachel Elam*,Michael Clemenshaw,Laura Carbone,Leighton James. Membranous nephropathy complicating relapsing polychondritis: A case report. J Clini Nephrol. 2021: doi: 10.29328/journal.jcn.1001080; 5: 084-087
  • Acyclovir Induced Acute Kidney Injury: A Case Report
    Ziauddin Mohammed*, Mariya Zoha Muskan and Megha Mohan Narayanan Ziauddin Mohammed*, Mariya Zoha Muskan, Megha Mohan Narayanan. Acyclovir Induced Acute Kidney Injury: A Case Report. Arch Pharm Pharma Sci. 2024: doi: 10.29328/journal.apps.1001048; 8: 001-002
  • Kidney Biopsy in Autosomal Dominant Polycystic Kidney Disease
    Laalasa Varanasi*, Gabriel Loeb, Vighnesh Walavalkar, Nebil Mohammed, John Paul Lindsey II, Stephen Gluck, Thomas Lee Chi and Meyeon Park Laalasa Varanasi*, Gabriel Loeb, Vighnesh Walavalkar, Nebil Mohammed, John Paul Lindsey II, Stephen Gluck, Thomas Lee Chi, Meyeon Park. Kidney Biopsy in Autosomal Dominant Polycystic Kidney Disease. J Clini Nephrol. 2023: doi: 10.29328/journal.jcn.1001118; 7: 101-105
  • Management of temporomandibudar joint ankylosis with costo-chondral graft application: Case report and review of literature
    Nikolaos Kolomvos*, Agamemnon Chliaoutakis and Nikolaos Papadogeorgakis Nikolaos Kolomvos*,Agamemnon Chliaoutakis,Nikolaos Papadogeorgakis . Management of temporomandibudar joint ankylosis with costo-chondral graft application: Case report and review of literature. J Oral Health Craniofac Sci. 2020: doi: 10.29328/journal.johcs.1001030; 5: 001-005
  • Twin-stage technique for occlusal rehabilitation of a mutilated dentition – A case report
    Amarjeet Gambhir* and Gita Rani Amarjeet Gambhir*,Gita Rani. Twin-stage technique for occlusal rehabilitation of a mutilated dentition – A case report. J Oral Health Craniofac Sci. 2020: doi: 10.29328/journal.johcs.1001031; 5: 006-010

Read More

Most Viewed

Read More

Help ?